Market Cap | 6.35M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -13.08M | Forward P/E | -0.42 | EPS next Y | - | 50D Avg Chg | -9.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -36.00% |
Dividend | N/A | Price/Book | 0.39 | EPS next 5Y | - | 52W High Chg | -60.00% |
Recommedations | 2.00 | Quick Ratio | 10.24 | Shares Outstanding | 2.04M | 52W Low Chg | 13.00% |
Insider Own | 0.23% | ROA | -38.24% | Shares Float | 2.03M | Beta | 1.76 |
Inst Own | 10.27% | ROE | -63.96% | Shares Shorted/Prior | 2.54K/1.36K | Price | 3.11 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 8,075 | Target Price | 40.00 |
Oper. Margin | - | Earnings Date | Nov 13 | Volume | 4,712 | Change | 0.00% |
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.
HC Wainwright & Co. | Buy | Aug 16, 22 |
HC Wainwright & Co. | Neutral | Nov 17, 20 |
H.C. Wainwright | Neutral | Nov 17, 20 |
H.C. Wainwright | Buy | Dec 18, 19 |
H.C. Wainwright | Buy | Mar 21, 18 |